SEC Filing Summary: Revelation Biosciences, Inc. (REVB)
Business Context and Reporting Period
This Form 8-K, dated May 8, 2025, serves as a current report for Revelation Biosciences, Inc., a Delaware corporation headquartered in San Diego, California. The filing references the company's financial results for the three months ended March 31, 2025, which were announced via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification of the results rather than a detailed financial statement. The filing notes the existence of redeemable warrants (REVBW) exercisable for common stock at an exercise price of $193,200.00 per share.
Material Changes
The filing text does not provide specific data regarding material changes in financial position or operations compared to prior periods. It solely references the issuance of the press release containing the Q1 2025 results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed within the text of this 8-K form itself.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 8, 2025) for actual Q1 2025 financial figures.
- Verify the company's cash runway and burn rate, as these are not disclosed in the 8-K text.
- Confirm the status of the redeemable warrants (REVBW) and any potential dilution impact.
- Check for any subsequent filings that may incorporate the Q1 results by reference.